Last week’s hot topic on Lymphoma was about the Lymphoma and Leukemia Clinical Trials of Immunotherapy Drug to Treat Resistant Cancers Now Recruiting Patients written by Margarida Azevedo.
The article is centered around the three new clinical trials aiming to assess the safety and efficacy of a new cancer immunotherapy treatment, KTE-C19, in patients with three types of treatment-resistant blood cancers — refractory aggressive non-Hodgkin lymphoma (NHL), relapsed/refractory mantle cell lymphoma and relapsed/refractory B-precursor acute lymphoblastic leukemia.
All three trials, led by researchers at the University of California San Diego’s Moores Cancer Center in collaboration with Kite Pharma, and ongoing at three sites in California, Texas and Florida, are currently recruiting patients.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?